ArticleInternational journal of clinical and experimental medicine2015
Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Pooled it
- Article
- Exploring the 1-(4-Nitrophenyl)-3-arylprop-2-en-1-one Scaffold for the Selective Inhibition of Monoamine Oxidase B.ACS medicinal chemistry letters · 2024Article
- Design, Synthesis, and Biological Effect Studies of Novel Benzofuran-Thiazolylhydrazone Derivatives as Monoamine Oxidase Inhibitors.ACS omega · 2024Article
- An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.Archives of toxicology · 2018Review
- Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- Selegiline Ameliorates Depression-Like Behavior in Mice Lacking theFrontiers in behavioral neuroscience · 2017Article
- Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood-Brain Barrier in a Rat Model of Parkinson's Disease.CNS neuroscience & therapeutics · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta. We explored the neuroprotective effect of Selegiline and Piribedil, the Monoamine Oxidase Type B (MAO-B) and dopamine agonist to Parkinson disease (PD). After embryonic Wistar rat were induced by cerebrospinal fluid (CSF) from PD patients, Selegiline and Piribedil were administered to Wistar rat. Immunohistochemical staining, RT-PCR and western blot were adopted to analyze the changes of morphology, lactate dehydrogenase activity, tyrosine hydroxylase positive neurons rate, and tyrosine hydroxylase (TH) expression in Wistar rat. The two drugs do not affect the normal growth of dopamine neurons. Selegiline and Piribedil both decreased the injury caused by CSF of PD patients in Wistar rat. We observed decreased lactate dehydrogenase (LDH) activity, increased TH (+)/total cells ratio and increased the TH expression in treated Wistar rat with dose-dependent effects. The morphological changes of cells are consistent with above observation. Selegiline and Piribedil have neuroprotective effects to induced PD Wistar rat with dose-dependent effect. Selegiline demonstrated stronger neuroprotective effect than Piribedil, and the two drugs have potential treatment effect in clinical for PD patients.
Indexed as
Identifiers
25785014PMC4358469W73581072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.